ASH Registry Offers Insights on COVID‐19 in Patients with Hematologic Malignancies

For patients with blood cancers, the COVID‐19 mortality rate is approximately 20% overall and 33% for those who require hospitalization, according to new data from the ASH Research Collaborative COVID‐19 Registry for Hematology.

Detalles Bibliográficos
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley & Sons, Inc. 2020
Materias:
Conference Perspectives
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7869116/
https://www.ncbi.nlm.nih.gov/pubmed/33368829
http://dx.doi.org/10.1002/onco.13657
Descripción
Sumario:For patients with blood cancers, the COVID‐19 mortality rate is approximately 20% overall and 33% for those who require hospitalization, according to new data from the ASH Research Collaborative COVID‐19 Registry for Hematology.

Ejemplares similares